VENLO, Netherlands, July 14, 2016 /PRNewswire/ --
QIAGEN N.V. QGEN QIA plans as previously announced to release its report on results for the second quarter and first half of 2016 on Thursday, July 28, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). A conference call is planned for Friday, July 29, at 15:30 CET / 9:30 ET hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
Conference Call and Webcast Details
The conference call will begin at 15:30 CET / 9:30 ET on July 29, 2016.
Interested parties may listen to the call by dialing: +1-631-302-6547 (U.S.), +44-203-059-8128 (UK), +49-69-566-036-000 (Germany)
The webcast will be accessible at http://www.qiagen.com/de/about-us/investors/corporate-calendar.
A conference call replay will be available through August 4, 2016, by dialing:
+1-724-5589-653 (U.S.), +44-121-260-4861 (UK), +49-69-710-488-70 (Germany) (passcode: 194059#).
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Contact:
John Gilardi
Vice President Corporate Communications and Investor Relations
+49-2103-29-11711
+1-240-686-2222
Email: ir@qiagen.com
Dr. Sarah Fakih
Associate Director Investor Relations
+49-2103-29-11457
Email: ir@qiagen.com
SOURCE Qiagen
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
